Search results

1. Aadi gets an ADC makeover

   … Only ADC in clinic is AbbVie’s ABBV-706 ( early data at ASCO 2024 ) Source: OncologyPipeline & company …

   
    

   Madeleine Armstrong
    
   - 03/20/2025 - 15:37

2. Make or break time for Caribou

   … disappointed with its allogeneic Car-T project CB-010 at ASCO 2024 , will soon have a chance to redeem itself. In … 14.8mth Note: *2L LBCLC subgroup. Source: ASCO 2024 & product labels.   Caribou has therefore …

   
    

   Madeleine Armstrong
    
   - 03/25/2025 - 15:35

3. Zymeworks follows Mersana

   … M7152 Merck KGaA Preclinical, disclosed at ASCO 2024 investor event Undisclosed ADC …

   
    

   Jacob Plieth
    
   - 10/01/2025 - 11:55

4. KAT6 catalysts to kick off 2025

   … with Faslodex, and monotherapy data were last reported at ASCO 2024, showing an 11% ORR . The good news is that …

   
    

   Jacob Plieth
    
   - 01/08/2025 - 13:52

5. Affimed needs more time with AFM24

   … of AFM24 + Tecentriq in relapsed NSCLC   ASCO 2024 + Jun 2024 PR Dec 2024 PR …

   
    

   Madeleine Armstrong
    
   - 12/18/2024 - 15:56

6. Triple meeting 2024 – Zai Lab impresses in small cell

   … Presentation venue Triple meeting 2024 ESMO 2023 ASCO 2024 ORR 74% (14/19)* 40% (40/99) …

   
    

   Madeleine Armstrong
    
   - 10/29/2024 - 13:27

7. Sanofi goes deeper into the lead

   … SSTR Ph2 AlphaMedix-02 in NETs Data at ASCO 2024: ORR 56% (20/36) in radioligand-therapy naive pts; …

   
    

   Madeleine Armstrong
    
   - 10/23/2024 - 14:40

8. AbbVie has Met phase 3, again

   … tumours: CRC, GEA, NSCLC Teliso-A +/- Avastin Data at ASCO 2024 in CRC (>35% ORR in high cMet expressers at doses …

   
    

   Madeleine Armstrong
    
   - 02/25/2025 - 10:35

9. IMS 2024 – Darzalex fights back against Sarclisa

   … Venue International Myeloma Society 2024 ASCO 2024 mPFS NR vs 52.6 months with VRd NR vs … VRd=Velcade, Revlimid & dexamethasone. Source: IMS 2024 & ASCO 2024. Conferences Trial …

   
    

   Madeleine Armstrong
    
   - 04/24/2025 - 13:34

10. Akeso builds up its ivonescimab ambitions again

    … 2nd-line NSCLC Ivonescimab + chemo Chemo Data ASCO 2024: ORR 51% vs 35%, PFS 7.1 vs 4.8mo; OS 17.1 vs …

    
     

    Madeleine Armstrong
     
    - 09/26/2024 - 12:56